Orchard Plans EU Submission For GSK-Originated MLD Gene Therapy
Executive Summary
Orchard is aiming to get its second autologous gene therapy on the market next year, with a European filing for MLD and a BLA to follow.
You may also be interested in...
Genespire Glides Into Gene Therapy Space
Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.
Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.